Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab's high-concentration 100 mg/mL formulation aims to provide an enhanced yet
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions